• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

ASCO 2023 – Bicara eyes head and neck niche

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 05, 2023 at 10:02: AM
via Bicara raised $108m in March on the back of encouraging early data on BCA101, a bispecific antibody that hits both EGFR and TGF-beta. With strong responses now confirmed in head and neck cancer, and a registrational trial potentially on the horizon, the group is already thinking about its next financing.

article source
 




Top Bottom
Back
Quote